Durable complete responses from therapy with combined epratuzumab and rituximab-Reference-Cited by-同舟云学术

Durable complete responses from therapy with combined epratuzumab and rituximab

Published:2008-11-15 Issue:10 Volume:113 Page:2714-2723
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Leonard John P.,Schuster Stephen J.,Emmanouilides Christos,Couture Felix,Teoh Nick,Wegener William A.,Coleman Morton,Goldenberg David M.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.23890/fullpdf

Reference32 articles.

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project;Blood.,1997

2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program;McLaughlin;J Clin Oncol.,1998

3. Differential expression of CD22 indolent and aggressive non-Hodgkin's lymphoma (NHL): implications for targeted therapy;Cessano;Blood.,2002

4. CD22, a B cell-specific receptor, mediates adhesion and signal transduction;Clark;J Immunol.,1993

5. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction;Tedder;Adv Immunol.,2005

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacology to Practice;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

2. Follicular lymphoma: the diminishing role of chemotherapy;Journal of Cancer Metastasis and Treatment;2022

3. Targeting CD22 for the Treatment of B-Cell Malignancies;ImmunoTargets and Therapy;2021-07

4. Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies;Journal of Fungi;2021-03-05

5. Advances in targeted therapy for malignant lymphoma;Signal Transduction and Targeted Therapy;2020-03-06